AbSci has developed a proprietary engineered E. coli expression system, SoluPro™ that will allow for an easily optimizable and scalable production of soluble recombinant proteins. Our game-changing core technology allows proteins (including antibodies and enzymes) to be produced at a fraction of their current cost, without any corresponding loss in performance characteristics. In addition, use of the versatile SoluPro™ platform accelerates the R&D process by enabling rapid access to soluble protein for screening purposes. These therapeutic proteins and antibodies are used in cancer and hormone therapies, as well as autoimmune and blood disorder therapies.
Initial Public Offering (Nasdaq: ABSI) in July 2021